Triple M Syndrome: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 12: Line 12:


==Historical Perspective==
==Historical Perspective==
Immune checkpoint inhibitors represent a form of immunotherapy that gained FDA approval in 2011. These medications are accompanied by various side effects. Among these, Triple M emerges as a rare yet lethal side effect linked to checkpoint inhibitors. The initial documented instance of Triple M occurred in 2016.
Immune checkpoint inhibitors represent a form of immunotherapy that gained FDA approval in 2011. These medications are accompanied by various side effects. Among these, Triple M emerges as a rare yet lethal side effect linked to checkpoint inhibitors. The initial documented instance of Triple M occurred in 2016.<ref name="pmid34378270">{{cite journal|author=Pathak R, Katel A, Massarelli E, Villaflor VM, Sun V, Salgia R|title=Immune Checkpoint Inhibitor-Induced Myocarditis with Myositis/Myasthenia Gravis Overlap Syndrome: A Systematic Review of Cases.|journal=Oncologist|year=2021|volume=26|issue=12|pages=1052-1061|pmid=34378270|doi=10.1002/onco.13931|pmc=8649039|url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=34378270}}</ref>


==Classification==
==Classification==

Revision as of 04:22, 10 August 2023

WikiDoc Resources for Triple M Syndrome

Articles

Most recent articles on Triple M Syndrome

Most cited articles on Triple M Syndrome

Review articles on Triple M Syndrome

Articles on Triple M Syndrome in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Triple M Syndrome

Images of Triple M Syndrome

Photos of Triple M Syndrome

Podcasts & MP3s on Triple M Syndrome

Videos on Triple M Syndrome

Evidence Based Medicine

Cochrane Collaboration on Triple M Syndrome

Bandolier on Triple M Syndrome

TRIP on Triple M Syndrome

Clinical Trials

Ongoing Trials on Triple M Syndrome at Clinical Trials.gov

Trial results on Triple M Syndrome

Clinical Trials on Triple M Syndrome at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Triple M Syndrome

NICE Guidance on Triple M Syndrome

NHS PRODIGY Guidance

FDA on Triple M Syndrome

CDC on Triple M Syndrome

Books

Books on Triple M Syndrome

News

Triple M Syndrome in the news

Be alerted to news on Triple M Syndrome

News trends on Triple M Syndrome

Commentary

Blogs on Triple M Syndrome

Definitions

Definitions of Triple M Syndrome

Patient Resources / Community

Patient resources on Triple M Syndrome

Discussion groups on Triple M Syndrome

Patient Handouts on Triple M Syndrome

Directions to Hospitals Treating Triple M Syndrome

Risk calculators and risk factors for Triple M Syndrome

Healthcare Provider Resources

Symptoms of Triple M Syndrome

Causes & Risk Factors for Triple M Syndrome

Diagnostic studies for Triple M Syndrome

Treatment of Triple M Syndrome

Continuing Medical Education (CME)

CME Programs on Triple M Syndrome

International

Triple M Syndrome en Espanol

Triple M Syndrome en Francais

Business

Triple M Syndrome in the Marketplace

Patents on Triple M Syndrome

Experimental / Informatics

List of terms related to Triple M Syndrome

For patient information, click Insert page name here

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Muhammad Waleed, M.B.B.S.[2]

Synonyms and keywords: myocarditis with myositis and/or myasthenia gravis overlap syndrome (IM3OS)

Overview

Myocarditis-myositis-myasthenia gravis (Triple-M) overlap syndrome occurs as a rare complication in patients receiving immune checkpoint inhibitors (ICI).

Historical Perspective

Immune checkpoint inhibitors represent a form of immunotherapy that gained FDA approval in 2011. These medications are accompanied by various side effects. Among these, Triple M emerges as a rare yet lethal side effect linked to checkpoint inhibitors. The initial documented instance of Triple M occurred in 2016.[1]

Classification

Pathophysiology

Genetics

Associated Conditions

Gross Pathology

Microscopic Pathology

Causes

Life Threatening Causes

Life-threatening causes include conditions which may result in death or permanent disability within 24 hours if left untreated.

Common Causes

Causes by Organ System

Cardiovascular No underlying causes
Chemical / poisoning No underlying causes
Dermatologic No underlying causes
Drug Side Effect No underlying causes
Ear Nose Throat No underlying causes
Endocrine No underlying causes
Environmental No underlying causes
Gastroenterologic No underlying causes
Genetic No underlying causes
Hematologic No underlying causes
Iatrogenic No underlying causes
Infectious Disease No underlying causes
Musculoskeletal / Ortho No underlying causes
Neurologic No underlying causes
Nutritional / Metabolic No underlying causes
Obstetric/Gynecologic No underlying causes
Oncologic No underlying causes
Opthalmologic No underlying causes
Overdose / Toxicity No underlying causes
Psychiatric No underlying causes
Pulmonary No underlying causes
Renal / Electrolyte No underlying causes
Rheum / Immune / Allergy No underlying causes
Sexual No underlying causes
Trauma No underlying causes
Urologic No underlying causes
Dental No underlying causes
Miscellaneous No underlying causes

Causes in Alphabetical Order

  • A...
  • Z...

Make sure that each diagnosis is linked to a page.

Differentiating type page name here from other Diseases

Epidemiology and Demographics

Age

Gender

Race

Developed Countries

Developing Countries

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

If available, the diagnostic criteria are provided here.

History

A directed history should be obtained to ascertain

Symptoms

"Type symptom here" is pathognomonic of the "type disease name here".

"Type non specific symptoms" may be present.

Past Medical History

Family History

Social History

Occupational

Alcohol

The frequency and amount of alcohol consumption should be characterized.

Drug Use

Smoking

Allergies

Physical Examination

Appearance of the Patient

Vital Signs

Skin

Head

Eyes

Ear

Nose

Mouth

Throat

Heart

Lungs

Abdomen

Extremities

Neurologic

Genitals

Other

Laboratory Findings

Electrolyte and Biomarker Studies

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Pharmacotherapy

Acute Pharmacotherapies

Chronic Pharmacotherapies

Surgery and Device Based Therapy

Indications for Surgery

Pre-Operative Assessment

Post-Operative Management

Transplantation

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

References

  1. Pathak R, Katel A, Massarelli E, Villaflor VM, Sun V, Salgia R (2021). "Immune Checkpoint Inhibitor-Induced Myocarditis with Myositis/Myasthenia Gravis Overlap Syndrome: A Systematic Review of Cases". Oncologist. 26 (12): 1052–1061. doi:10.1002/onco.13931. PMC 8649039 Check |pmc= value (help). PMID 34378270 Check |pmid= value (help).